Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Gilead, Vir Biotechnology establish collaboration for chronic HBV » 08:11
01/12/21
01/12
08:11
01/12/21
08:11
GILD

Gilead

$62.50 /

-0.54 (-0.86%)

, VIR

Vir Biotechnology

$28.30 /

+0.46 (+1.65%)

Gilead Sciences (GILD)…

Gilead Sciences (GILD) and Vir Biotechnology (VIR) announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus. The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naive people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead's investigational TLR-8 agonist; VIR-2218, Vir's investigational small interfering ribonucleic acid; and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead's Vemlidy. The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen and HBV DNA from the serum. Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial.

ShowHide Related Items >><<
VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

01/11/21 Piper Sandler
Piper says hard for Gilead investors to ascribe long-term value to Veklury
01/04/21 Guggenheim
Gilead upgraded to Buy from Neutral at Guggenheim
12/22/20 Citi
Gilead price target lowered to $72 from $75 at Citi
12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

12/24/20 Baird
Baird maintains 'profound skepticism' of Vir's COVID antibody after Lilly data
10/07/20 Goldman Sachs
Goldman says Lilly comments support need for multiple COVID-19 antibody makers
10/07/20 H.C. Wainwright
Vir Biotechnology price target raised to $100 from $80 at H.C. Wainwright
10/05/20
Fly Intel: Top five analyst initiations
VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

  • 08
    Jul
VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

Hot Stocks
Gilead, Vir collaborate to explore combination strategies for HBV cure » 08:10
01/12/21
01/12
08:10
01/12/21
08:10
GILD

Gilead

$62.50 /

-0.54 (-0.86%)

, VIR

Vir Biotechnology

$28.30 /

+0.46 (+1.65%)

Gilead Sciences (GILD)…

Gilead Sciences (GILD) and Vir Biotechnology (VIR) announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus, HBV. The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naive people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead's investigational TLR-8 agonist; VIR-2218, Vir's investigational small interfering ribonucleic acid; and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead's Vemlidy. The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum. Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial. "Gilead has a two-decade commitment to people with hepatitis B and we have worked tirelessly to bring new treatments forward with the goal of helping to improve their lives," said Anuj Gaggar, Vice President, Clinical Research, Virology at Gilead Sciences. "We believe that selgantolimod and VIR-2218 have the potential to be best-in-class therapeutics and could provide a compelling new combination approach to a functional cure for HBV." "We are enthusiastic about this collaboration," said Phil Pang, MD, PhD, Chief Medical Officer of Vir Biotechnology. "We believe a functional cure for the majority of patients will require a reduction of the levels of circulating viral proteins together with an immune boost to stimulate the production of new T-cells that can bring the infection under control. We believe that this collaboration with Gilead adds a novel and significant new combination to our efforts to find a cure for HBV." HBV affects more than 290 million people worldwide. Globally, HBV is a leading cause of liver cancer and each year it is estimated that more than 800,000 people die of HBV-related liver disease. While current antiviral therapies result in sustained HBV viral suppression, they rarely completely clear the virus and therefore people with HBV require lifelong therapy. The safety and efficacy of selgantolimod and VIR-2218 have not been established. They are investigational compounds, not approved by the U.S. Food and Drug Administration or any other regulatory authority. U.S. Important Safety Information and Indication for VEMLIDY

ShowHide Related Items >><<
VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

01/11/21 Piper Sandler
Piper says hard for Gilead investors to ascribe long-term value to Veklury
01/04/21 Guggenheim
Gilead upgraded to Buy from Neutral at Guggenheim
12/22/20 Citi
Gilead price target lowered to $72 from $75 at Citi
12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

12/24/20 Baird
Baird maintains 'profound skepticism' of Vir's COVID antibody after Lilly data
10/07/20 Goldman Sachs
Goldman says Lilly comments support need for multiple COVID-19 antibody makers
10/07/20 H.C. Wainwright
Vir Biotechnology price target raised to $100 from $80 at H.C. Wainwright
10/05/20
Fly Intel: Top five analyst initiations
VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

  • 08
    Jul
VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

VIR Vir Biotechnology
$28.30 /

+0.46 (+1.65%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

GILD Gilead
$62.50 /

-0.54 (-0.86%)

Monday
Recommendations
Piper says hard for Gilead investors to ascribe long-term value to Veklury » 14:30
01/11/21
01/11
14:30
01/11/21
14:30
GILD

Gilead

$62.86 /

-0.185 (-0.29%)

After Gilead raised its…

After Gilead raised its 2020 product sales guidance by $1.075B, or 5%, at the midpoint relative to the outlook communicated in Q3, Piper Sandler analyst Tyler Van Buren noted that product sales excluding Veklury for COVID-19 would have been down 3% year-over-year, which is why he suspects shares are flat following the guidance hike. Veklury's unpredictability, along with competitive pressures from antibody products and hopeful waning of cases from the pandemic, make it hard for investors to ascribe long-term value to the franchise, said Van Buren, who views Trodelvy as the most important near-term driver of Gilead's value. He keep an Overweight rating and $80 price target on the shares.

ShowHide Related Items >><<
GILD Gilead
$62.86 /

-0.185 (-0.29%)

GILD Gilead
$62.86 /

-0.185 (-0.29%)

01/04/21 Guggenheim
Gilead upgraded to Buy from Neutral at Guggenheim
12/22/20 Citi
Gilead price target lowered to $72 from $75 at Citi
12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
12/17/20 Maxim
Galapagos price target lowered to $140 from $170 at Maxim
GILD Gilead
$62.86 /

-0.185 (-0.29%)

GILD Gilead
$62.86 /

-0.185 (-0.29%)

GILD Gilead
$62.86 /

-0.185 (-0.29%)

GILD Gilead
$62.86 /

-0.185 (-0.29%)

Options
Gilead call volume above normal and directionally bullish » 13:05
01/11/21
01/11
13:05
01/11/21
13:05
GILD

Gilead

$63.06 /

+0.02 (+0.03%)

Bullish option flow…

Bullish option flow detected in Gilead with 32,911 calls trading, 1.6x expected, and implied vol increasing almost 4 points to 31.35%. Jan-21 60 calls and Jan-21 65 calls are the most active options, with total volume in those strikes near 7,800 contracts. The Put/Call Ratio is 0.23. Earnings are expected on February 2nd.

ShowHide Related Items >><<
GILD Gilead
$63.06 /

+0.02 (+0.03%)

GILD Gilead
$63.06 /

+0.02 (+0.03%)

01/04/21 Guggenheim
Gilead upgraded to Buy from Neutral at Guggenheim
12/22/20 Citi
Gilead price target lowered to $72 from $75 at Citi
12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
12/17/20 Maxim
Galapagos price target lowered to $140 from $170 at Maxim
GILD Gilead
$63.06 /

+0.02 (+0.03%)

GILD Gilead
$63.06 /

+0.02 (+0.03%)

GILD Gilead
$63.06 /

+0.02 (+0.03%)

GILD Gilead
$63.06 /

+0.02 (+0.03%)

On The Fly
Fly Intel: Pre-market Movers » 08:54
01/11/21
01/11
08:54
01/11/21
08:54
MESO

Mesoblast

$8.65 /

-0.26 (-2.92%)

, LLY

Eli Lilly

$166.35 /

+0.465 (+0.28%)

, SECO

Secoo Holding

$2.41 /

+0.04 (+1.69%)

, WBAI

500.com

$12.07 /

+0.06 (+0.50%)

, GILD

Gilead

$63.04 /

+0.49 (+0.78%)

, DXCM

DexCom

$388.37 /

+0.59 (+0.15%)

, TWTR

Twitter

$51.50 /

-0.83 (-1.59%)

, LULU

Lululemon

$365.57 /

-1.62 (-0.44%)

, NCR

NCR Corp.

$37.16 /

-0.6 (-1.59%)

, CATM

Cardtronics

$41.07 /

+5.41 (+15.17%)

Check out this morning's…

ShowHide Related Items >><<
WBAI 500.com
$12.07 /

+0.06 (+0.50%)

TWTR Twitter
$51.50 /

-0.83 (-1.59%)

SECO Secoo Holding
$2.41 /

+0.04 (+1.69%)

NCR NCR Corp.
$37.16 /

-0.6 (-1.59%)

MESO Mesoblast
$8.65 /

-0.26 (-2.92%)

LULU Lululemon
$365.57 /

-1.62 (-0.44%)

LLY Eli Lilly
$166.35 /

+0.465 (+0.28%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

DXCM DexCom
$388.37 /

+0.59 (+0.15%)

CATM Cardtronics
$41.07 /

+5.41 (+15.17%)

MESO Mesoblast
$8.65 /

-0.26 (-2.92%)

12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
12/18/20 H.C. Wainwright
Mesoblast price target lowered to $16 from $20 at H.C. Wainwright
12/04/20
Fly Intel: Top five analyst downgrades
LLY Eli Lilly
$166.35 /

+0.465 (+0.28%)

01/07/21 KeyBanc
Veeva initiated with an Overweight at KeyBanc
01/05/21 Stifel
Stifel starts 'truly unique' AbCellera at Buy with $59 price target
12/24/20 Baird
Baird maintains 'profound skepticism' of Vir's COVID antibody after Lilly data
12/16/20 Mizuho
Eli Lilly price target raised to $164 from $156 at Mizuho
SECO Secoo Holding
$2.41 /

+0.04 (+1.69%)

WBAI 500.com
$12.07 /

+0.06 (+0.50%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

01/04/21 Guggenheim
Gilead upgraded to Buy from Neutral at Guggenheim
12/22/20 Citi
Gilead price target lowered to $72 from $75 at Citi
12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
12/17/20 Maxim
Galapagos price target lowered to $140 from $170 at Maxim
DXCM DexCom
$388.37 /

+0.59 (+0.15%)

01/07/21 Piper Sandler
DexCom G6 users slightly more satisfied than Libre users, says Piper Sandler
01/06/21 UBS
DexCom upgraded to Buy from Neutral at UBS
12/10/20 Stephens
Stephens says 'best is yet to come' for DexCom after investor day
12/10/20 Stifel
DexCom has 'significantly more' growth still to come, says Stifel
TWTR Twitter
$51.50 /

-0.83 (-1.59%)

01/08/21 Baird
Twitter price target raised to $58 from $39 at Baird
01/07/21 Citi
Citi opens 'negative Catalyst Watch' on Twitter ahead of results
01/05/21 Morgan Stanley
Twitter price target raised to $50 from $42 at Morgan Stanley
12/16/20
Fly Intel: Top five analyst upgrades
LULU Lululemon
$365.57 /

-1.62 (-0.44%)

01/05/21 Deutsche Bank
Lululemon named short-term investment idea at Deutsche Bank
12/14/20 Argus
Lululemon price target raised to $400 from $380 at Argus
12/11/20 B. Riley Securities
Lululemon price target raised to $409 from $385 at B. Riley Securities
12/11/20 BMO Capital
Lululemon price target raised to $275 from $228 at BMO Capital
NCR NCR Corp.
$37.16 /

-0.6 (-1.59%)

01/11/21 JPMorgan
NCR bid for Cardtronics makes sense, says JPMorgan
01/11/21 Stephens
NCR Corp. price target raised to $49 from $39 at Stephens
12/14/20 Craig-Hallum
Par Technology price target raised to $75 from $55 at Craig-Hallum
12/04/20 RBC Capital
NCR Corp. price target raised to $41 from $32 at RBC Capital
CATM Cardtronics
$41.07 /

+5.41 (+15.17%)

12/15/20 DA Davidson
Cardtronics downgraded to Neutral from Buy at DA Davidson
12/10/20 DA Davidson
Cardtronics price target raised to $39 from $34 at DA Davidson
TWTR Twitter
$51.50 /

-0.83 (-1.59%)

NCR NCR Corp.
$37.16 /

-0.6 (-1.59%)

MESO Mesoblast
$8.65 /

-0.26 (-2.92%)

LULU Lululemon
$365.57 /

-1.62 (-0.44%)

LLY Eli Lilly
$166.35 /

+0.465 (+0.28%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

DXCM DexCom
$388.37 /

+0.59 (+0.15%)

CATM Cardtronics
$41.07 /

+5.41 (+15.17%)

TWTR Twitter
$51.50 /

-0.83 (-1.59%)

NCR NCR Corp.
$37.16 /

-0.6 (-1.59%)

LULU Lululemon
$365.57 /

-1.62 (-0.44%)

LLY Eli Lilly
$166.35 /

+0.465 (+0.28%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

WBAI 500.com
$12.07 /

+0.06 (+0.50%)

TWTR Twitter
$51.50 /

-0.83 (-1.59%)

NCR NCR Corp.
$37.16 /

-0.6 (-1.59%)

MESO Mesoblast
$8.65 /

-0.26 (-2.92%)

LULU Lululemon
$365.57 /

-1.62 (-0.44%)

LLY Eli Lilly
$166.35 /

+0.465 (+0.28%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

DXCM DexCom
$388.37 /

+0.59 (+0.15%)

CATM Cardtronics
$41.07 /

+5.41 (+15.17%)

TWTR Twitter
$51.50 /

-0.83 (-1.59%)

MESO Mesoblast
$8.65 /

-0.26 (-2.92%)

LULU Lululemon
$365.57 /

-1.62 (-0.44%)

LLY Eli Lilly
$166.35 /

+0.465 (+0.28%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

Earnings
Gilead raises FY20 adjusted EPS view to $6.98 - $7.08 from $6.25 - $6.60 » 06:05
01/11/21
01/11
06:05
01/11/21
06:05
GILD

Gilead

$63.04 /

+0.49 (+0.78%)

FY20 consensus $6.61.…

FY20 consensus $6.61. Raises FY20 product sales view to $24.3B-$24.35B from $23B-$23.5B, consensus $23.71B.

ShowHide Related Items >><<
GILD Gilead
$63.04 /

+0.49 (+0.78%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

01/04/21 Guggenheim
Gilead upgraded to Buy from Neutral at Guggenheim
12/22/20 Citi
Gilead price target lowered to $72 from $75 at Citi
12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
12/17/20 Maxim
Galapagos price target lowered to $140 from $170 at Maxim
GILD Gilead
$63.04 /

+0.49 (+0.78%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

GILD Gilead
$63.04 /

+0.49 (+0.78%)

Over a week ago
Hot Stocks
Kite, Oxford BioTherapeutics enter research collaboration » 08:10
01/06/21
01/06
08:10
01/06/21
08:10
GILD

Gilead

$60.01 /

-0.14 (-0.23%)

Kite, a Gilead company,…

Kite, a Gilead company, and Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immuno-oncology, or IO, and antibody-drug conjugate, or ADC-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five novel oncology drug targets, previously identified using OBT's OGAP discovery platform, and generate antibodies against these targets. Kite and Gilead will have the exclusive right to develop and commercialize therapies based on these targets or antibodies. Under the terms of the agreement, OBT will receive an upfront payment and will be eligible to receive additional payments based on achievement of certain discovery, clinical and regulatory milestones, as well as royalties on future potential sales.

ShowHide Related Items >><<
GILD Gilead
$60.01 /

-0.14 (-0.23%)

GILD Gilead
$60.01 /

-0.14 (-0.23%)

01/04/21 Guggenheim
Gilead upgraded to Buy from Neutral at Guggenheim
12/22/20 Citi
Gilead price target lowered to $72 from $75 at Citi
12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
12/17/20 Maxim
Galapagos price target lowered to $140 from $170 at Maxim
GILD Gilead
$60.01 /

-0.14 (-0.23%)

GILD Gilead
$60.01 /

-0.14 (-0.23%)

GILD Gilead
$60.01 /

-0.14 (-0.23%)

GILD Gilead
$60.01 /

-0.14 (-0.23%)

Upgrade
Gilead upgraded to Buy from Neutral at Guggenheim » 06:24
01/04/21
01/04
06:24
01/04/21
06:24
GILD

Gilead

$58.23 /

+1.59 (+2.81%)

Guggenheim analyst…

Guggenheim analyst Whitney Ijem upgraded Gilead to Buy from Neutral.

ShowHide Related Items >><<
GILD Gilead
$58.23 /

+1.59 (+2.81%)

GILD Gilead
$58.23 /

+1.59 (+2.81%)

12/22/20 Citi
Gilead price target lowered to $72 from $75 at Citi
12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
12/17/20 Maxim
Galapagos price target lowered to $140 from $170 at Maxim
12/17/20 Oppenheimer
Gilead price target lowered to $100 from $105 at Oppenheimer
GILD Gilead
$58.23 /

+1.59 (+2.81%)

GILD Gilead
$58.23 /

+1.59 (+2.81%)

GILD Gilead
$58.23 /

+1.59 (+2.81%)

GILD Gilead
$58.23 /

+1.59 (+2.81%)

Options
Unusually active option classes on open December 31st » 09:40
12/31/20
12/31
09:40
12/31/20
09:40
ENPH

Enphase Energy

$172.91 /

+ (+0.00%)

, BILI

Bilibili

$94.38 /

+ (+0.00%)

, PSTH

Pershing Square Tontine Holdings

$26.94 /

-0.025 (-0.09%)

, LMND

Lemonade

$129.97 /

+0.0002 (+0.00%)

, FCX

Freeport McMoRan

$26.54 /

+ (+0.00%)

, NIO

NIO Inc.

$48.37 /

+ (+0.00%)

, GILD

Gilead

$56.64 /

+ (+0.00%)

, RCL

Royal Caribbean

$73.75 /

+ (+0.00%)

, AMZN

Amazon.com

$3,286.09 /

+2.37 (+0.07%)

, NNDM

Nano Dimension

$9.53 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Enphase Energy (ENPH), Bilibili (BILI), Pershing Square Tontine Holdings (PSTH), Lemonade (LMND), Freeport McMoRan (FCX), NIO (NIO), Gilead (GILD), Royal Caribbean (RCL), Amazon (AMZN), and Nano Dimension (NNDM).

ShowHide Related Items >><<
RCL Royal Caribbean
$73.75 /

+ (+0.00%)

PSTH Pershing Square Tontine Holdings
$26.94 /

-0.025 (-0.09%)

NNDM Nano Dimension
$9.53 /

+ (+0.00%)

NIO NIO Inc.
$48.37 /

+ (+0.00%)

LMND Lemonade
$129.97 /

+0.0002 (+0.00%)

GILD Gilead
$56.64 /

+ (+0.00%)

FCX Freeport McMoRan
$26.54 /

+ (+0.00%)

ENPH Enphase Energy
$172.91 /

+ (+0.00%)

BILI Bilibili
$94.38 /

+ (+0.00%)

AMZN Amazon.com
$3,286.09 /

+2.37 (+0.07%)

ENPH Enphase Energy
$172.91 /

+ (+0.00%)

12/24/20 Roth Capital
Roth Capital calls Generac, Sunnova, Enphase favorite 2021 solar ideas
12/24/20 Roth Capital
Enphase Energy price target raised to $220 from $160 at Roth Capital
12/21/20 Roth Capital
ITC/PTC extensions likely included in COVID relief package, says Roth Capital
12/15/20 Roth Capital
Solar tax credit extension would be positive surprise, says Roth Capital
BILI Bilibili
$94.38 /

+ (+0.00%)

12/16/20 Morgan Stanley
Bilibili named Research Tactical Idea at Morgan Stanley
11/19/20 Daiwa
Bilibili upgraded to Buy from Outperform at Daiwa
11/19/20 Citi
Bilibili price target raised to $60 from $58 at Citi
10/21/20 HSBC
Bilibili initiated with a Buy at HSBC
PSTH Pershing Square Tontine Holdings
$26.94 /

-0.025 (-0.09%)

LMND Lemonade
$129.97 /

+0.0002 (+0.00%)

11/23/20 Morgan Stanley
Root initiated with an Equal Weight at Morgan Stanley
11/12/20 Piper Sandler
Lemonade price target raised to $71 from $63 at Piper Sandler
11/02/20 Piper Sandler
Lemonade initiated with an Overweight at Piper Sandler
10/15/20
Fly Intel: Pre-market Movers
FCX Freeport McMoRan
$26.54 /

+ (+0.00%)

12/16/20 Johnson Rice
Freeport McMoRan initiated with a Buy at Johnson Rice
11/11/20 Goldman Sachs
Freeport McMoRan initiated with a Conviction Buy at Goldman Sachs
10/23/20 BMO Capital
Freeport McMoRan price target raised to $23 from $19 at BMO Capital
10/23/20 Deutsche Bank
Freeport McMoRan price target raised to $20 from $18 at Deutsche Bank
NIO NIO Inc.
$48.37 /

+ (+0.00%)

12/21/20 Wedbush
Tesla price target raised to $715 from $560 at Wedbush
12/14/20 Daiwa
NIO Inc. initiated with a Buy at Daiwa
12/14/20 Deutsche Bank
Deutsche starts Xpeng at Buy, sees multiple electric vehicle winners
12/02/20 UBS
UBS downgrades Xpeng to Neutral, raises price target to $59
GILD Gilead
$56.64 /

+ (+0.00%)

12/22/20 Citi
Gilead price target lowered to $72 from $75 at Citi
12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
12/17/20 Maxim
Galapagos price target lowered to $140 from $170 at Maxim
12/17/20 Oppenheimer
Gilead price target lowered to $100 from $105 at Oppenheimer
RCL Royal Caribbean
$73.75 /

+ (+0.00%)

10/30/20 Stifel
CDC lifting 'no sail order' a 'clear positive' for cruise liners, says Stifel
10/30/20 Deutsche Bank
Royal Caribbean price target raised to $46 from $43 at Deutsche Bank
10/16/20 Deutsche Bank
Deutsche sees Covid newsflow remaining drag on cruise stocks
10/15/20 Berenberg
Royal Caribbean price target raised to $60 from $45 at Berenberg
AMZN Amazon.com
$3,286.09 /

+2.37 (+0.07%)

12/22/20 Wells Fargo
Microsoft's own semis 'a competitive headwind' for Intel, says Wells Fargo
12/16/20 Baird
Baird would be a buyer of Teladoc amid weakness caused by Amazon report
12/14/20 BMO Capital
BMO downgrades Disney after recent run, names new top media pick
12/03/20 Rosenblatt
Ambarella price target raised to $100 from $82 at Rosenblatt
NNDM Nano Dimension
$9.53 /

+ (+0.00%)

RCL Royal Caribbean
$73.75 /

+ (+0.00%)

NNDM Nano Dimension
$9.53 /

+ (+0.00%)

NIO NIO Inc.
$48.37 /

+ (+0.00%)

LMND Lemonade
$129.97 /

+0.0002 (+0.00%)

GILD Gilead
$56.64 /

+ (+0.00%)

FCX Freeport McMoRan
$26.54 /

+ (+0.00%)

ENPH Enphase Energy
$172.91 /

+ (+0.00%)

BILI Bilibili
$94.38 /

+ (+0.00%)

AMZN Amazon.com
$3,286.09 /

+2.37 (+0.07%)

  • 14
    Dec
  • 14
    Oct
  • 31
    Aug
  • 22
    Jul
  • 02
    Jul
  • 11
    Jun
  • 05
    Feb
RCL Royal Caribbean
$73.75 /

+ (+0.00%)

PSTH Pershing Square Tontine Holdings
$26.94 /

-0.025 (-0.09%)

NIO NIO Inc.
$48.37 /

+ (+0.00%)

LMND Lemonade
$129.97 /

+0.0002 (+0.00%)

GILD Gilead
$56.64 /

+ (+0.00%)

FCX Freeport McMoRan
$26.54 /

+ (+0.00%)

BILI Bilibili
$94.38 /

+ (+0.00%)

AMZN Amazon.com
$3,286.09 /

+2.37 (+0.07%)

RCL Royal Caribbean
$73.75 /

+ (+0.00%)

PSTH Pershing Square Tontine Holdings
$26.94 /

-0.025 (-0.09%)

NIO NIO Inc.
$48.37 /

+ (+0.00%)

LMND Lemonade
$129.97 /

+0.0002 (+0.00%)

GILD Gilead
$56.64 /

+ (+0.00%)

FCX Freeport McMoRan
$26.54 /

+ (+0.00%)

ENPH Enphase Energy
$172.91 /

+ (+0.00%)

BILI Bilibili
$94.38 /

+ (+0.00%)

AMZN Amazon.com
$3,286.09 /

+2.37 (+0.07%)

RCL Royal Caribbean
$73.75 /

+ (+0.00%)

PSTH Pershing Square Tontine Holdings
$26.94 /

-0.025 (-0.09%)

NNDM Nano Dimension
$9.53 /

+ (+0.00%)

NIO NIO Inc.
$48.37 /

+ (+0.00%)

LMND Lemonade
$129.97 /

+0.0002 (+0.00%)

GILD Gilead
$56.64 /

+ (+0.00%)

FCX Freeport McMoRan
$26.54 /

+ (+0.00%)

ENPH Enphase Energy
$172.91 /

+ (+0.00%)

BILI Bilibili
$94.38 /

+ (+0.00%)

AMZN Amazon.com
$3,286.09 /

+2.37 (+0.07%)

Recommendations
Gilead price target lowered to $72 from $75 at Citi » 06:00
12/22/20
12/22
06:00
12/22/20
06:00
GILD

Gilead

$58.53 /

-0.55 (-0.93%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal lowered the firm's price target on Gilead Sciences to $72 from $75 and keeps a Buy rating on the shares. The analyst updated his model model to reflect the recent decision to stop pursuing filgotinib in rheumatoid arthritis. While this impacts topline growth by 1% point, its impact on bottom-line is minimal due to associated cost savings, Bansal tells investors in a research note. The analyst thinks Gilead's new oncology business could drive growth and start to make the company "look attractive" as it gets back on the growth path starting in 2023.

ShowHide Related Items >><<
GILD Gilead
$58.53 /

-0.55 (-0.93%)

GILD Gilead
$58.53 /

-0.55 (-0.93%)

12/18/20 Truist
Gilead price target lowered to $62 from $67 at Truist
12/17/20 Maxim
Galapagos price target lowered to $140 from $170 at Maxim
12/17/20 Oppenheimer
Gilead price target lowered to $100 from $105 at Oppenheimer
12/16/20 BMO Capital
Gilead price target lowered to $62 from $64 at BMO Capital
GILD Gilead
$58.53 /

-0.55 (-0.93%)

GILD Gilead
$58.53 /

-0.55 (-0.93%)

GILD Gilead
$58.53 /

-0.55 (-0.93%)

GILD Gilead
$58.53 /

-0.55 (-0.93%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.